ENDV (Endonovo Therapeutics) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Endonovo Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was $-0.00 Mil. Endonovo Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Endonovo Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Endonovo Therapeutics's current FCF Yield % is 477.27%.

The historical rank and industry rank for Endonovo Therapeutics's FCF Margin % or its related term are showing as below:

ENDV' s FCF Margin % Range Over the Past 10 Years
Min: -25575 Med: -1086.35 Max: 8750
Current: 8750

During the past 13 years, the highest FCF Margin % of Endonovo Therapeutics was 8750.00%. The lowest was -25575.00%. And the median was -1086.35%.

ENDV's FCF Margin % is ranked better than
99.61% of 1018 companies
in the Biotechnology industry
Industry Median: -139.165 vs ENDV: 8750.00

Endonovo Therapeutics FCF Margin % Historical Data

The historical data trend for Endonovo Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics FCF Margin % Chart

Endonovo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-820.65

-446.99

-1,352.05

-502.96

87.14

Endonovo Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-368.89	-3,250.00	8,766.67	-	-

Competitive Comparison of Endonovo Therapeutics's FCF Margin %

For the Biotechnology subindustry, Endonovo Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Endonovo Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Endonovo Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	0.122	/	0.14
	=	87.14 %

Endonovo Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.001	/	0
	=	%

Endonovo Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Endonovo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367

Website

https://www.endonovo.com

Endonovo Therapeutics Inc is an USA-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.

Executives

Alan Brian Collier	director, 10 percent owner, officer: CEO	6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann	10 percent owner, officer: President	6320 CANOGA AVENUE, WOODLAND HILLS CA 91367